P = .02). Compared with reference filgrastim, the mean total costs per patient and per day of use were 6.1% and 10.8% less for filgrastim-sndz (P = .07 and P < .001), respectively, and were marginally higher for tbo-filgrastim (2.7% and 2.3%, respectively; P = .64 and P = .50, respectively).
State-of-the art treatment of multiple myeloma (MM) involves induction with triplet-based regimens using combinations of immunomodulatory drugs and proteasome inhibitors, which have shown improved progression-free survival and overall survival compared with doublet regimens in the newly diagnosed (ND) and relapsed and refractory (RR) setting. [1] [2] [3] Carfilzomib is a selective proteasome inhibitor approved by the US Food and Drug Administration for use in the carfilzomib, lenalidomide, and dexamethasone (KRd) regimen for the treatment of RRMM. 3, 4 We previously reported early data on this phase 2 study of 45 patients with NDMM.
5
Herein, we expand on our initial results and present the longterm durability of minimal residual disease-negative complete remissions (MRD-negative CRs) and time to progression, the last characterized by depth of response, age, and cytogenetic risk profile.
Methods | This study of KRd with lenalidomide maintenance (KRd-r) enrolled patients with treatment-naive NDMM regardless of eligibility for autologous stem cell transplant (NCT01402284). 5 Patients received eight 28-day cycles of 
MRD-negative CR
Patients who experienced MRD-negative CR by the end of carfilzomib, lenalidomide, and dexamethasone induction (8 cycles) had a significantly longer time to disease progression, with a 78% reduction in risk of progression (hazard ratio, 0.22; 95% CI, 0.07-0.69; P = .005). Hatch marks on the curves indicate censored data. 2, 8, 9, 15, 16) , and lenalidomide, 25 mg (days 1-21), followed by 2 years of maintenance therapy with lenalidomide, 10 mg (days 1-21). Transplant-eligible patients underwent harvest after 4 cycles of therapy. Minimal residual disease-negative complete remission was assessed by multicolor flow cytometry (bone marrow aspirate; 10 −5 sensitivity) after induction, at 1 and 2 years of lenalidomide maintenance therapy, and annually thereafter. The National Cancer Institute institutional review board approved the study, and participants provided written informed consent.
Results | Forty-five patients who met eligibility criteria were enrolled; among these, 27 (60%) were men and mean (SD) age was 61 (12) years 5 ; median (95% CI) follow-up was 5.2 (4.7-5.6) years. Treatment with KRd-r led to rapid, deep, and durable overall response rate and sustained MRD-negative CRs. All but 1 patient (overall response rate, 98%; 95% CI, 88%-100%) experienced a partial response or better as the best objective response, with a mean (SD) of 4.4 (1.1) weeks to partial response or better. The median duration of response was 65.7 months (95% CI, 55.6 months to not estimable). Twentyeight of the 45 patients (62%; 95% CI, 47%-76%) experienced MRD-negative CR. To date, durability of MRD-negative CR has been observed at up to 70 months, with a median duration of more than 4 years (52.4 months; 95% CI, 35.3-61.6). Patients who experienced MRD negativity by the end of cycle 8 had a 78% decrease in risk of progression ( Figure 1) . Moreover, treatment with KRd-r was associated with unprecedented progression-free duration and overall survival, with a median time to progression of more than 5.5 years (67.3 months; 95% CI, 51.0 months to not estimable). Median overall survival was not reached because, as of this writing,40 of the 45 patients are still alive. However, at a 6-year milestone, the probability of survival was 84%. Deep responses of MRD-negative CR and long progression-free durations occurred irrespective of age or adverse cytogenetic risk factors (Figure 2) . In general, KRd-r was well tolerated, with manageable low-grade toxic effects and no grade 3 or greater peripheral neuropathy, the primary end point.
5
Discussion | First-line treatment of NDMM with the modern and highly efficacious KRd regimen incorporating a "by default delayed" autologous stem cell transplant strategy led to high rates of MRD-negative CR, which were sustained with a median duration of more than 4 years. We confirm that attaining MRD negativity with at least 10 −5 sensitivity is crucial for deriving long-term benefit, as shown previously.
6
In the present study, MRD-negative CR was strongly associated with a delay in progression and with an estimated greater than 80% reduction in the risk of disease progression. Furthermore, and of clinical importance, our findings indicate that these deep responses and long progression-free durations are attainable regardless of patient age or cytogenetic risk category. Taken together, these findings stress the importance of using highly efficacious triplet-based regimens for these subcategories of NDMM and avoiding de-escalation of triplet regimen and dosage based on patient age or other factors.
Our results compare favorably with autologous stem cell transplant-based regimens. The major limitation is the singlearm nature of the study design, and cross-trial comparisons are limited. Given the impressive activity of KRd-r in NDMM, we subsequently designed a trial using KRd-r for patients with high-risk smoldering MM, which is currently enrolling participants (NCT01572480). (54) 14 (74) Deep and sustained MRD-negative responses and prolonged TTP after treatment with a drug regimen of carfilzomib, lenalidomide, and dexamethasone with lenalidomide maintenance therapy occurred irrespective of age group or adverse cytogenetic risk factors. This depiction of TTP for important myeloma subgroups of age and poor cytogenetic risk shows no difference in hazard ratios (HRs) for TTP for either subgroup. Patients older than 65 years derived a clinical benefit similar to that of younger patients in terms of MRD-negative CR and TTP. Moreover, patients with myeloma who had high cytogenetic risk factors of 17p deletion or translocations of (4;14), (14;16), and (14;20) derived the same levels of deep response and prolonged progression-free duration as those with standard risk. a Calculated using the Fisher exact test.
b Calculated using the log-rank test. J Clin Oncol. 2018; 36(8) 7] months; log-rank P < .001) and after adjusting for age, comorbidities, and disease aggressiveness (odds ratio, 0.26; 95% CI, 0.13-0.50). We believe that the results merit the following comments and discussion. First, we are concerned as to the severity of anemia at the time of assessment because it may affect physical and cognitive function of patients, 2 and symptoms due to anemia could be amenable to red blood cell transfusions. Second, patients with hematologic cancers often experience invasion of the central nervous system (CNS) by their disease, and it can be related to worse prognosis as well as possible adverse influence on cognitive function.
3,4
Therefore, to interpret the significance of mortality and cognitive function in the study 1 cohort, it would be crucial to assess the presence or absence of CNS invasion. Third, it is not clear whether the authors included patients who have received CNS-directed therapy (such as irradiation, intrathecal chemotherapy, or high-dose methotrexate and cytarabine) at the time of assessment, because CNSdirected therapy may have influenced cognitive functions of patients.
5 Finally, the causes of deaths are of concern especially for patients receiving intensive treatment. Whether patients died with active hematologic cancers may provide 1 clue to elucidate the mechanism of adverse effects of deteriorated cognitive function in the study 1 cohort.
